Daptomycin intravenous

Drug Profile

Daptomycin intravenous

Alternative Names: Cubicin; daptomycin for injection; Deptomycin; LY-146032; MK-3009

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer AstraZeneca; Banyu; Cubist Pharmaceuticals; Merck & Co; Novartis; Sunovion Pharmaceuticals Canada
  • Class Antibacterials; Cyclic peptides; Lipopeptides; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Bacteraemia; Bacterial endocarditis; Gram-positive infections; Skin and soft tissue infections; Staphylococcal infections
  • Phase III Osteomyelitis
  • Discontinued Community-acquired pneumonia; Urinary tract infections

Most Recent Events

  • 01 Dec 2016 Cubist Pharmaceuticals completes a phase III trial in Osteomyelitis (In adolescents, In children, In infants) in USA, Argentina, Australia, Brazil, Bulgaria, Chile, Colombia, Estonia, France, Germany, Greece, Hungary, Israel, Italy, Latvia, Moldova, Panama, Peru, Romania, Russia, Spain, Slovenia, South Africa, South Korea, Spain, Turkey, Ukraine and United Kingdom (IV) (NCT01922011)
  • 15 Sep 2016 First Generic equivalent is available in USA
  • 22 Oct 2015 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of daptomycin intravenous for use in paediatric patients with Skin and soft tissue infections in EU
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top